Tag: clinical trials
Landmark TAPUR™ Study Adds Two New Precision Drug Arms
ASCO, the American Society of Clinical Oncology, has expanded the Targeted Agent and Profiling Utilization Registry (TAPUR™) study.
The TAPUR study (NCT02693535), a phase 2...
Antibody-Drug Conjugates in Gastric Cancer: Clinical Progress, Resistance, and the Road...
Antibody-Drug Conjugates in Gastric Cancer: Clinical Progress, Resistance, and the Road Ahead
Takeaways from the 3rd Antibody-Drug Conjugate (ADC) Toxicity Summit
3rd Antibody-Drug Conjugate (ADC) in Boston, MA, brought together a group of diverse yet deeply specialized experts who shared their knowledge, clinical insights, and technical experience with remarkable openness and clarity.
First Patient Enrolled in Phase 1 Clinical Trial with AK138D1, ...
A first patient has been enrolled in the Phase I clinical trial of AK138D1 for the treatment of advanced malignancies in Australia. AK138D1 is being developed by Akeso. It is the company's first antibody-drug conjugate (ADC) to enter clinical studies.
SABCS 2024: Disitamab Vedotin Demonstrates Clinically Meaningful Results in the Treatment...
In 2022, with an estimated 2.3 million new cases and nearly 700.000 deaths globally, breast cancer emerged as the most prevalent cancer after lung...
In the War Against Brain Cancer, Accelerated Clinical Trials Are a...
More than 1.4 million people live with malignant brain tumors. Glioblastoma – the cancer that killed Senators John McCain and Ted Kennedy – is...
Pivotal Trial of Enfortumab Vedotin Shows Positive Topline Results in Locally...
The first cohort of patients in a pivotal phase II single-arm clinical trial, known as EV-201, shows positive topline results. EV-201 is an ongoing...
Study looks at Efficacy and Metabolism of Azonafide-based ADCs in Microgravity
A new study is investigating the efficacy and metabolism of azonafide-based antibody-drug conjugates (ADCs) in microgravity. The investigators seeks to activate immunogenic cell death...
European Commission Approves Label Variation for Brentuximab Vedotin
The European Commission (EC) has, earlier this week, approved a Type II variation for brentuximab vedotin (Adcetris®; Takeda/Seattle Genetics) to include data on the...
Phase I Study Supports Therapeutic Potential of Polatuzumab Vedotin in non-Hodgkin...
Lymphoma - with its main forms Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) - is the most common blood cancer which occurs when cells...
